Propanc Biopharma, Inc. (PPCB) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$18.9M, or -$17.62 per diluted share. Operating activities generated -$5.7M of cash, leaving -$5.7M of free cash flow. At fiscal year end, Propanc Biopharma held $12.8M in total assets against $3.4M in total liabilities.
Open the full interactive Propanc Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Propanc Biopharma Key Stats
| Share Price | $0.41 |
|---|---|
| Market Cap | $463,530 |
| 52-Week Range | $0.41 – $45.75 |
| Shares Outstanding | 1.1 million (basic, 2026 Q4) |
Propanc Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | — |
| Operating Income | -$1.8M | -$2.0M | -$1.8M | -$1.5M | -$57.3M | -$18.2M |
| Pre-Tax Income | -$2.1M | -$2.7M | -$2.8M | -$1.9M | -$58.9M | -$18.9M |
| Income Tax | -$113,415 | -$54,977 | -$129,841 | -$129,132 | — | — |
| Net Income | -$2.4M | -$2.7M | -$2.7M | -$1.8M | -$58.9M | -$18.9M |
| Diluted EPS | -$40.00 | — | -$90.00 | $118440.50 | -$371.25 | -$17.62 |
Propanc Biopharma Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Net Income | -$4.8M | -$3.1M | -$6.4M | -$4.6M |
| Diluted EPS | -$9.75 | -$7.50 | -$7.00 | -$4.07 |
Propanc Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2,255 | $4,067 | — | — | — | — |
| Current Assets | $6,596 | $15,030 | $19,039 | $25,441 | $8.4M | $8.5M |
| Total Assets | $13,101 | $81,651 | $60,328 | $72,365 | $19.6M | $12.8M |
| Current Liabilities | $3.1M | $3.1M | $3.2M | $3.8M | $5.6M | $3.4M |
| Total Long-Term Debt | $624,583 | $984,260 | $390,539 | $399,325 | $537,921 | $200,650 |
| Total Liabilities | $3.1M | $3.1M | $3.2M | $3.9M | $5.7M | $3.4M |
| Shareholders' Equity | -$3.1M | -$3.0M | -$3.1M | -$3.8M | $13.9M | $9.4M |
Propanc Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.1M | -$1.4M | -$1.1M | — | -$405,168 | -$5.7M |
| Cash From Investing | — | — | — | — | — | -$4,933 |
| Cash From Financing | $1.1M | $1.5M | $1.1M | — | $490,756 | $6.5M |
| Free Cash Flow | — | — | — | $0 | — | -$5.7M |
Figures from Propanc Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Propanc Biopharma financials page for every line item.
Propanc Biopharma Company Profile
| Ticker | PPCB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Camberwell, Victoria, Australia |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001517681 |
Frequently Asked Questions
What was Propanc Biopharma's net income in fiscal 2026?
Propanc Biopharma reported net income of -$18.9M for fiscal 2026.
What was Propanc Biopharma's earnings per share (EPS) in fiscal 2026?
Propanc Biopharma's diluted EPS was -$17.62 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Propanc Biopharma generate in fiscal 2026?
Propanc Biopharma generated -$5.7M of free cash flow in fiscal 2026.
How much debt does Propanc Biopharma have?
Propanc Biopharma reported $200,650 of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Propanc Biopharma are outstanding?
Propanc Biopharma reported a weighted average of 1.1 million basic shares outstanding in 2026 Q4.
What is Propanc Biopharma's market cap?
Based on its latest closing price, Propanc Biopharma (PPCB) has a market capitalization of about $463,530.
When does Propanc Biopharma's fiscal year end?
Propanc Biopharma's fiscal year end, as registered with the SEC, is June 30.
Where is Propanc Biopharma headquartered?
Propanc Biopharma lists its business address in Camberwell, Victoria, Australia in its SEC filings.